Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.

MLA

Sharifian, Azadeh, et al. “Postoperative NEOadjuvant TEMozolomide Followed by Chemoradiotherapy versus Upfront Chemoradiotherapy for Glioblastoma Multiforme (NEOTEM) Trial: Interim Results.” Neuro-Oncology Advances, vol. 6, no. 1, Nov. 2024, p. vdae195. EBSCOhost, https://doi.org/10.1093/noajnl/vdae195.

APA

Sharifian, A., Kazemian, A., Farzin, M., Amirkhani, N., Farazmand, B., Naderi, S., Khalilian, A., Pourrashidi, A., Amjad, G., Kolahdouzan, K., Abyaneh, R., Jablonska, P. A., & Ghalehtaki, R. (2024). Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results. Neuro-Oncology Advances, 6(1), vdae195. https://doi.org/10.1093/noajnl/vdae195

Chicago

Sharifian, Azadeh, Ali Kazemian, Mostafa Farzin, Nikan Amirkhani, Borna Farazmand, Soheil Naderi, Alireza Khalilian, et al. 2024. “Postoperative NEOadjuvant TEMozolomide Followed by Chemoradiotherapy versus Upfront Chemoradiotherapy for Glioblastoma Multiforme (NEOTEM) Trial: Interim Results.” Neuro-Oncology Advances 6 (1): vdae195. doi:10.1093/noajnl/vdae195.